Welcome to our dedicated page for Siga Technologie SEC filings (Ticker: SIGA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Government contracts, milestone payments, and biodefense stockpile deliveries make SIGA Technologies disclosures uniquely complex. If you have ever typed “SIGA Technologies SEC filings explained simply” or hunted for the latest BARDA award inside a “SIGA Technologies quarterly earnings report 10-Q filing,” you know how time-consuming it can be to trace TPOXX revenue or pinpoint when executives exercised options. Stock Titan’s AI removes the guesswork.
Our platform ingests every document the moment it hits EDGAR, from a routine 10-Q to an unexpected 8-K that announces fresh procurement funds. AI-powered summaries translate pharma jargon into clear language, so understanding SIGA Technologies SEC documents with AI becomes a three-minute task, not a three-hour read. Need real-time alerts for “SIGA Technologies Form 4 insider transactions real-time” or a deeper look at “SIGA Technologies executive stock transactions Form 4”? One click delivers the data, while expert commentary highlights why an insider buy might precede a material event.
Go beyond headlines with focused insights that matter to biodefense investors: contract backlog trends inside the “SIGA Technologies annual report 10-K simplified,” R&D spend trajectories across quarters, or governance details in the “SIGA Technologies proxy statement executive compensation.” You can also drill into “SIGA Technologies 8-K material events explained,” compare revenue guidance through each “SIGA Technologies earnings report filing analysis,” and monitor “SIGA Technologies insider trading Form 4 transactions” without wading through dense footnotes. With AI-powered summaries, real-time filing updates, and full coverage of every SEC form, Stock Titan turns SIGA’s specialized disclosures into actionable intelligence investors can trust.
BioCardia, Inc. (BCDA) Form 4 filing – insider purchase and warrant acquisition
President, Chief Executive Officer and Director Peter Altman reported buying 24,096 common shares of BioCardia on 30 June 2025 at a purchase price of $2.075 per share (transaction code P, private placement). Concurrently, he received 24,096 warrants with an exercise price of $1.95 per share and an expiration date of 30 June 2030. The warrants were issued on a one-for-one basis with the purchased common shares as part of a private placement that also involved other qualified institutional buyers and accredited investors.
Following the transactions, Altman now holds 165,862 common shares directly and 95,612 warrants that, if fully exercised, could convert into the same number of common shares.
The filing reflects insider participation in the company’s latest capital raise, signalling management’s willingness to commit personal capital. However, the issuance of additional shares and long-dated warrants increases BioCardia’s potential fully diluted share count, which investors should monitor when evaluating future per-share metrics.
Form 4 filing overview – SIGA Technologies, Inc. (SIGA)
Executive Vice President & Chief Scientific Officer Dennis E. Hruby reported routine equity transactions dated July 1 2025.
- RSU vesting (Code M): 32,258 restricted stock units converted to common shares at a cost basis of $0.00.
- Share withholding for taxes (Code F): 10,467 shares automatically sold/withheld at $6.49 per share to satisfy statutory tax obligations.
- Net share change: +21,791 shares, increasing direct ownership to 191,047 common shares.
- The underlying RSU grant was issued on May 11 2023 and vested 50 % on July 1 2024 and the remaining 50 % on July 1 2025; no derivative units remain outstanding after this conversion.
The filing reflects standard incentive-plan vesting mechanics rather than open-market buying or discretionary selling.
FAQ
What is the current stock price of Siga Technologie (SIGA)?
What is the market cap of Siga Technologie (SIGA)?
What is SIGA Technologies' primary focus?
What is TPOXX and what is its approved use?
How does SIGA generate revenue?
What partnerships support SIGA's product development?
In which markets does SIGA primarily operate?
How does SIGA address global health security concerns?
What are the safety and efficacy measures for SIGA's therapies?
How does SIGA differentiate itself from competitors in biotechnology?
